Факторы риска развития гепатита B у пациентов на гемодиализе по данным систематического обзора
https://doi.org/10.23946/2500-0764-2019-4-2-107-119
Аннотация
Ключевые слова
Об авторах
Д. В. Квашнина
ФГБОУВО «Приволжский исследовательский медицинскийуниверситет» Министерства здравоохранения Российской Федерации
Россия
Россия
КвашнинаДаръя Валерьевна - кандидат медицинских наук, старший преподаватель кафедры эпидемиологии, микробиологии и доказательной медицины.
603081, Н. Новгород, пр. Гагарина, д.70
О. В. Ковалишена
ФГБОУВО «Приволжский исследовательский медицинскийуниверситет» Министерства здравоохранения Российской Федерации
Россия
Россия
Ковалишена Ольга Васильевна - доктор медицинских наук, доцент, заведующий кафедрой эпидемиологии, микробиологии и доказательной медицины.
Нижний Новгород
Н. В. Саперкин
Университет Утрехта
Нидерланды
Саперкин Николай Валентинович - кандидат медицинских наук, доцент, врач-исследователь
Нидерланды
Саперкин Николай Валентинович - кандидат медицинских наук, доцент, врач-исследователь
Список литературы
1. Нефрология. Клинические рекомендации / под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. Москва: ГЭОТАР-Медиа, 2016. 816 с..
2. Хроническая болезнь почек: избранные главы нефрологии / Н.А. Томилина. Москва: ГЭОТАР-Медиа, 2017. 507 с.
3. Томилина H.A., Андрусев A.M., Перегудова Н.Г., Шинкарев М.Б. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 2010-2015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии российского диализного общества, часть первая II Нефрология и диализ. 2017. Т. 19, № S. С. 1-95.
4. Rinonce НТ, Yano Y, Utsumi Т, Heriyanto DS, Anggorowati N, Widasari DI, et al. Hepatitis В and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. J Med Virol. 2013; 85 (8): 1348-1361.
5. Bohlke M, Uliano G, Barcellos FC. Hemodialysis catheter-related infection: prophylaxis, diagnosis and treatment. J Vase Access. 2015; 16 (5): 347-355. doi: 10.5301/jva.5000368.
6. Gallieni M, Brenna I, Brunini F, Mezzina N, Pasho S, Giordano A. Dialysis central venous catheter types and performance. J Vase Access. 2014; 15 (Suppl 7): 140-146. doi: 10.5301/jva.5000262.
7. Murea M, James KM, Russell GB, Byrum GV, Yates JE, Tuttle NS, et al. Risk of catheter-related bloodstream infection in elderly patients on hemodialysis. Clin J Am Soc Nephrol. 2014; 9 (4): 764-770. doi: 10.2215/CJN.07710713.
8. Keyvani H, Agah S, Kabir A, Alavian SM. Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis В infection in hemodialysis patients: a nationwide study. Ann Hepatol. 2013; 12(2): 213-219.
9. Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015; 3 (3): 93-105. doi: 10.1515/jtim-2015-0018.
10. Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Factors affecting effectiveness of vaccination against hepatitis В virus in hemodialysis patients. World J Gastroenterol. 2014; 20 (34): 12018-12025. doi: 10.3748/wjg.v20.i34.12018.
11. Djalalinia S, Ramezan Ghorbani N, Tajbakhsh R, Modirian M, Esmaeili Abdar Z, Mahdavi Gorabi A, et al. Hepatitis В Virus Infection in Iranian Hemodialysis Patients: a Systematic Review and Meta-Analysis. Iran J Kidney Dis. 2018; 12 (1): 1-9.
12. Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget. 2017; 8 (6): 10692-10702. doi: 10.18632/oncotarget.12896.
13. Fabrizi F, Donato FM, Messa P. Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2017; 16 (1): 21-47. doi: 10.5604/16652681.1226813.
14. Cai QC, Zhao SQ, Shi TD, Ren H. Relationship between hepatitis B virus infection and chronic kidney disease in Asian populations: a meta-analysis. Ren Fail. 2016; 38 (10): 15811588. doi: 10.1080/0886022X.2016.1229548.
15. Chavez-Gomez NL, Cabello-Lopez A, Gopar-Nieto R. Aguilar-Madrid G, Marin-Lopez KS, Aceves-Valdez M, et al. Chronic kidney disease in Mexico and its relation with heavy metals. Rev Med Inst Mex Seguro Soc. 2017; 55 (6): 725-734.
16. Mikolajczyk, AE, Aronsohn, Al. Current Management of Chronic Hepatitis В and C in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2015; 22 (5): 352-360. doi: 10.1053/j.ackd.2015.06.008.
17. Зуева Л.П., Рахманова А.Г., Колосовская E.H. и др. Эпидемиологическая оценка распространенности вирусных гепатитов В и С у персонала и пациентов в стационарах Санкт-Петербурга II Эпидемиология и инфекционные болезни. 2012. № 2. С. 41-45.
18. Мукомолов С.Л., Левакова И.А., Синайская E.B., Сулягина Л.Г., Кислый П.Н., Тимаховская Г.Ю. и др. Эпидемиологическая характеристика вирусных гепатитов В и С в отделениях гемодиализа в Санкт-Петербурге в современный период. Часть 1. Регистрация гемоконтактных вирусных гепатитов и серологические маркеры вирусных гепатитов В и С у пациентов отделений гемодиализа II Инфекция и иммунитет. 2011. Т. 1, №2. С. 143-150. doi: 10.15789/2220-7619-2011-2-143-150.
19. Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015; 38 (1): 1-7. doi: 10.5301/ijao.5000376.
20. Feng Y, Shi X, Shi J, Gao L, Liu G, Cheng Y, et al. Immunogenicity, antibody persistence, and safety of the 60 pg hepatitis В vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017; 16 (10). 1045-1052. doi: 10.1080/14760584.2017.1367667.
21. Cordova E, Miglia I, Festuccia F, Sarlo MG. Scornavacca G, Punzo G, et al. Hepatitis В vaccination in haemodialysis patients: an underestimated problem. Factors influencing immune responses in ten years of observation in an Italian haemodialysis centre and literature review. Ann Ig. 2017; 29 (1): 27-37. doi: 10.7416/ai.2017.2129.
22. Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014; 25 (1): 185-191.
23. Костинов М.П., Тарасова, A.A. Рекомендации по вакцинации детей с хроническими заболеваниями почек II Эпидемиология и вакцинопрофилактика. 2014. № 3 (76). С. 109-111.
24. Чингаева Г.Н., Абеуова Б.А., Hay-шабаева А.Е., Кабулбаев К.А. Особенности иммунного статуса у детей на гемодиализе до и после вакцинации против гепатита В II Международный журнал прикладных и фундаментальных исследований. 2013. № 5. С. 52-55.
25. Достиев У.А., Достиев A.P., Каримов A.M. Характеристика иммунных нарушений у пациентов при терминальной стадии хронической почечной недостаточности II Трансплантология. 2016. № 4. С. 58-62.
26. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). Higgins JP, Green S, editor(s). The Cochrane Collaboration, 2011. Accessed: https://training.cochrane.org/handbook.
27. Реброва О.Ю., Федяева B.K. Вопросник для оценки риска систематических ошибок в нерандомизированных сравнительных исследованиях: русскоязычная версия шкалы Ньюкасл-Оттава II Медицинские технологии. Оценка и выбор. 2016. № 3 (25). С. 14-19.
28. Downes MJ, Brennan ML, Williams НС, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016; (6): e011458. doi: 10.1136/bmjopen-2016-011458.
29. RevMan. 5.3 User Guid. Computer program. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Accessed: https://community.cochrane.org/sites/default/files/uploads/inline-files/RevMan_5.3_User_Guide.pdf.
30. Gasim GI, Hamdan HZ, Hamdan SZ, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections among hemodialysis patients in Khartoum, Sudan. J Med Virol. 2012; 84(1): 52-55. doi: 10.1002/jmv.22256.
31. Carrilho FJ, Moraes CR, Pinho JR, Mello IM, Bertolini DA, Lemos MF, et al. Hepatitis В virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health. 2004. 4: 13. doi: 10.1186/1471-2458-4-13.
32. Alashek WA, McIntyre CW, Taal MW. Hepatitis В and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012; 20 (12): 265. doi: 10.1186/1471-2334-12-265.
33. Duong CM, Olszyna D, McLaws ML. Hepatitis В and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health. 2015; 27 (15): 192. doi: 10.1186/S12889-015-1532-9.
34. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, et al. Viral hepatitis C and В among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl. 2014; 25 (3): 672-679.
35. Daglar D, Ergani A, Demirbakan H, Ozhak Baysan B, Ongflt G, Ko^ak H, et al. Investigation of hepatitis В and hepatitis C virus infections by serological and molecular methods in hemodialysis patients. Mikrobiyol Bui. 2014; 48 (1): 143-150. doi: 10.5578/mb.5619.
36. Cordeiro VM, Martins B, Teles SA, Martins RMB, Cruvinel KPS, Matos MAD, et al. Decline in hepatitis В and C prevalence among hemodialysis patients in Tocantins, Northern Brazil. Revista do Institute de Medicina Tropical de Sao Paulo. 2018; 60:e36. doi: 10.1590/S1678-9946201860036.
37. Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS, et al. Hepatitis В and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles. Mem Inst Oswaldo Cruz. 2003; 98 (5): 599-603.
38. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis В virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz. 2006; 101 (6): 689-692.
39. Busek SU, Baba EH, Tavares Filho HA, Pimenta L, Salomao A, Correa-Oliveira R, et al. Hepatitis C and hepatitis В virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2002; 97 (6): 775-778. doi: 10.1590/S0074-02762002000600003.
40. Чингаева Г.Н., Нугманова A.M., Алимжанова Э.Б., Кулкаева М.Н., Досым С.М., Исмаилова Д.Б. и др. Вирусный гепатит В в детских отделениях гемодиализа республики Казахстан. Клиническая медицина Казахстана. 2014. № Sl-1. С. 74-75.
41. Зубкин М.Л. Проблемы вакцинопрофилактики гепатита В в условиях лечения программным гемодиализом II Нефрология и диализ. 2003. Т. 5, № 1. С 24-32.
42. А1 Hijazat М, Ajlouni YM. Hepatitis В infection among patients receiving chronic hemodialysis at the Royal Medical Services in Jordan. Saudi J Kidney Dis Transpl. 2008; 19 (2): 260-267.
43. Teles SA, Martins RM, Gomes SA, Gaspar AM, Araujo NM, Souza KP, et al. Hepatitis В virus transmission in Brazilian hemodialysis units: serological and molecular follow-up. J Med Virol. 2002. 68 (1). 41-49. doi: 10.1002/jmv.l0168.
44. Castro-Figueiredo JF, Moyses-Neto M, Gomes UA, Spalini-Ferraz A, Nardin-Batista ME, Coimbra-Gaspar AM, et al. Hepatitis B virus infection in hemodialysis units: clinical features, epidemiological markers and general control measures. Braz J Med Biol Res. 1986;19 (6): 735-742.
45. Alvarado-Esquivel C, Sablon E, Conde-Gonzalez CJ, Juarez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S. Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis В virus genotype H. World J Gastroenterol. 2006; 12 (40): 6540-6545. doi: 10.3748/wjg.vl2.i40.6540.
46. Lusida MI, Surayah, Sakugawa H, Nagano-Fujii M, Soetjipto, Mulyanto, et al. Genotype and subtype analyses of hepatitis B virus (HBV) and possible coinfection of HBV and hepatitis C virus (HCV) or hepatitis D virus (HDV) in blood donors, patients with chronic liver disease and patients on hemodialysis in Surabaya, Indonesia. Microbiol Immunol. 2003; 47 (12): 969-975.
47. Ramalingam S, Leung T, Cairns H. Sibley P, Smith M, Ijaz S, et al. Transmission of hepatitis В virus (genotype E) in a haemodialysis unit. J Clin Virol. 2007; 40 (2): 105-109. doi: 10.1016/j.jcv.2007.07.012.
48. De Castro L, Araujo NM, Sabino RR, Alvarenga F, Yoshida CF, Gomes SA. Nosocomial spread of hepatitis В virus in two hemodialysis units, investigated by restriction fragment length polymorphism analysis. Eur J Clin Microbiol Infect Dis. 2000; 19 (7): 531-537.
49. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003; 38 (4): 506-510. doi: 10.1016/S0168-8278(02)00457-9.
50. MottaJS, Mello FC, Lago BV, Perez RM,Gomes SA, Figueiredo FF. Occult hepatitis В virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol. 2010; 25 (1): 101-106. doi: 10.1111/j.l440-1746.2009.05972.x.
51. Wang C, Sun J, Zhu B, Larsen S, Yu R, Wu J, et al. Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. Ren Fail. 2010; 32 (10): 1255-1264. doi: 10.3109/0886022X.2010.517354.
52. Feng Y, Shi X. Immunogenicity, antibody persistence, and safety of the 60 pg hepatitis В vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017; 16 (10); 1045-1052. doi: 10.1080/14760584.2017.1367667.
53. Asan A, Demirhan H, Sorkun HC, Ozkan S, Aydtn M, Akin D, et al. Factors affecting responsiveness to hepatitis В immunization in dialysis patients. Int Urol Nephrol. 2017; 49 (10): 1845-1850. doi: 10.1007/sll255-017-1616-9.
54. Cordova E, Miglia I, Festuccia F, Sarlo MG, Scornavacca G, Punzo G, et al. Hepatitis В vaccination in haemodialysis patients: an underestimated problem. Factors influencing immune responses in ten years of observation in an Italian haemodialysis centre and literature review. Ann Ig. 2017; 29 (1): 27-37. doi: 10.7416/ai.2017.2129.
55. Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014; 25 (1): 185-191.
56. Костинов М.П., Тарасова A.A. Вакцинация детей с гемобластозами. Эпидемиология и Вакцинопрофилактика. 2018. Т. 17, № 1. С. 74-75. doi: 10.31631/2073-3046-2018-17-1-74-75.
57. Наушабаева A.E., Абеуова Б.А., Чингаева Г.Н., Нурбекова А.А., Кабулбаев К.А. Нефритический синдром у детей: морфологические варианты и лечение II Клиническая нефрология. 2012. № 2. С. 60-63.
58. Anding К, Gross Р, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysison neutrophil phagocytosisand antimicrobial killing. Nephrol Dial Transplant. 2003; 18 (10): 2067-2073. doi: 10.1093/ndt/gfg330.
59. Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis В vaccine Sci-B-Vac, as compared to Engerix B, among vaccine naive and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018; 22 (1): 151-158. doi: 10.1007/sl0157-017-1416-7.
60. Zitt E, Hafner-Giessauf H, Wimmer B, Herr A, Horn S, Friedl C, et al. Response to active hepatitis В vaccination and mortality in incident dialysis patients. Vaccine. 2017; 35 (5): 814-820. doi: 10.1016/j.vaccine.2016.12.032.
61. Grzegorzewska AE, Jodlowska E, Mostowska A, Jagodzinski P. Effect of interferon A3 gene polymorphisms, rs8099917 and rsl2979860, on response to hepatitis В virus vaccination and hepatitis В or C virus infections among hemodialysis patients. Pol Arch Med Wewn. 2015; 125 (12): 894-902. doi: 10.20452/pamw.3205.
62. Zitt E, Sprenger-Mahr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis В immunisation in patients with chronic kidney disease. Vaccine. 2012; 30 (5): 931-935. doi: 10.1016/j.vaccine.2011.11.086.
63. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G. Inverse association of serum 25-hydroxyvitamin D with markers of inflammation and suppression of osteoclastic activity in hemodialysis patients. Iran J Kidney Dis. 2012; (6): 129-135.
64. Fabrizi F, Dixit V, Martin P, Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis В virusvaccine in dialysis patients. Aliment Pharmacol Ther. 2011; 33 (7): 815-821. doi: 10.1111/j.l365-2036.2011.04589.x.
65. Patel N, Assimon MM, Bruni E, McNutt LA, Mason DL. Incidence and clinical predictors of nonresponse to hepatitis B vaccination among patients receiving hemodialysis: importance of obesity. South Med J. 2015; 108 (9): 567-573. doi: 10.14423/SMJ.0000000000000343.
66. Asan A, Demirhan H, Sorkun HC, Ozkan S, Aydtn M, Akin D, et al. Factors affecting responsiveness to hepatitis В immunization in dialysis patients. Int Urol Nephrol. 2017; 49 (10): 1845-1850. doi: 10.1007/sll255-017-1616-9.
67. Fabrizi F, Dixit V, Martin Р, Jadoul М, Messa Р. Meta-analysis: the impact of nutritional status on the immune response to hepatitis В virus vaccine in chronic kidney disease. Dig Dis Sci. 2012; 57: 1366-1372. doi: 10.1007/sl0620-011-1987-l.
68. Ferreira TMB, Guimaraes TGS, Fontenele AMM, Salgado N Filho, Ferreira ASP, Costa АРМ. Does infection by the hepatitis C virus decrease the response of immunization against thehepatitis B virus in individuals undergoing dialysis? J Bras Nefrol. 2017; 39 (2): 141-145. doi: 10.5935/0101-2800.20170020.
69. Lin SY, Liu JH, Lin CC, Wang SM, Tsai CA, Chou CY, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011; 29: 3738-3741. doi: 10.1016/j.vaccine.2011.03.049.
70. Akoglu H, Dede F, Piskinpasa S, Falay MY, Odabas AR. Impact of low- or high-flux haemodialysis and online haemodiafiltration on inflammatory markers and lipid profile in chronic haemodialysis patients. Blood Purif. 2013; 35 (4): 258264. doi: 10.1159/000348453.
71. Fabrizi F, Dixit V, Martin P, Messa P. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res. 2012; 35 (6): 504-510. doi: 10.1159/000335956.
72. Fabrizi F, Dixit V, Messa P, Martin P. Hepatitis В virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine. 2012; 30(13): 2295-2300. doi: 10.1016/j.vaccine.2012.01.064.
73. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017; 167 (11): 794-804. doi: 10.7326/M17-1106
74. Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P. Recombinant Hepatitis В Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015; 40 (6): 584-592. doi: 10.1159/000368534.
Рецензия
Для цитирования:
Квашнина Д.В., Ковалишена О.В., Саперкин Н.В. Факторы риска развития гепатита B у пациентов на гемодиализе по данным систематического обзора. Фундаментальная и клиническая медицина. 2019;4(2):107-119. https://doi.org/10.23946/2500-0764-2019-4-2-107-119
For citation:
Kvashnina D.V., Kovalishena O.V., Saperkin N.V. Risk factors of hepatitis B in patients on hemodialysis: a systematic review. Fundamental and Clinical Medicine. 2019;4(2):107-119. (In Russ.) https://doi.org/10.23946/2500-0764-2019-4-2-107-119
Просмотров: 489
Послать статью по эл. почте 